Non-contraceptive oestrogen-containing preparations for controlling symptoms of premenstrual syndrome

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 3, 2017, Pages

  Naheed, Bushra ^a   Kuiper, Jan Herman ^a   Uthman, Olalekan A ^b   O'Mahony, Fidelma ^c   O'Brien, Patrick Michael Shaughn ^d  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^d KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; DRUG IMPLANT;

CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DRUG SAFETY; HUMAN; PATIENT SATISFACTION; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; WELLBEING; COMBINATION DRUG THERAPY; DRUG IMPLANT; FEMALE; LUTEAL PHASE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PREMENSTRUAL DYSPHORIC DISORDER; TRANSDERMAL PATCH;

ADMINISTRATION, ORAL; DRUG IMPLANTS; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMANS; LUTEAL PHASE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSDERMAL PATCH;

EID: 85014389011     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010503.pub2     Document Type: Review

References (36)

1. Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology 1990;15(5-6):489-93. 5283255
2. Magos AL, Brincat M, Studd JW. Treatment of the premenstrual syndrome by subcutaneous estradiol implants and cyclical oral norethisterone: placebo controlled study. British Medical Journal 1986;292(6536):1629-33. [PUBMED: 3087550]5283257
3. Panay N, Rees M, Domoney C, Zakaria F, Guilford S, Studd JW. A multicentre double-blind crossover study comparing 100μg transdermal oestradiol with placebo in the treatment of severe premenstrual syndrome. British Menopause Society Journal 2001;7(Suppl 3):19-20. 5283259
4. Smith RN, Studd JW, Zamblera D, Holland EF. A randomised comparison over 8 months of 100 micrograms and 200 micrograms twice weekly doses of transdermal oestradiol in the treatment of severe premenstrual syndrome. British Journal of Obstetrics and Gynaecology 1995;102(6):475-84. [PUBMED: 7632640]5283261
5. Watson NR, Studd JWW. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989;334(8665):730-2. 5283263
6. de Lignières B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. British Medical Journal (Research Edition) 1986;293(6561):1540. 5283265
7. Dennerstein L, Morse C, Burrows G, Oats J, Brown J, Smith M. Menstrual migraine: a double-blind trial of percutaneous estradiol. Gynecological Endocrinology 1988;2(2):113-20. 5283267
8. Domoney C, Panay N, Hawkins A, Studd J. Treatment of premenstrual syndrome with transdermal oestrogen. International Journal of Gynaecology & Obstetrics 2003;83(suppl 3):37-8. 5283269
9. Ensom MH, Chong G, Zhou D, Beaudin B, Shalansky S, Bai TR. Estradiol in premenstrual asthma: a double-blind, randomized, placebo-controlled, crossover study. Pharmacotherapy 2003;23(5):561-71. 5283271
10. Halbreich U, Freeman EW, Rapkin AJ, Cohen LS, Grubb GS, Bergeron R, et al. Continuous oral levonorgestrel/ethinyl estradiol for treating premenstrual dysphoric disorder. Contraception 2012;85(1):19-27. 5283273
11. Abraha I, Montedori A. Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ 2010;340:C2697.
12. ACOG . ACOG practice bulletin: premenstrual syndrome. International Journal of Gynaecology and Obstetrics 2001;73:183-91.
13. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:7454.
14. Deeks JJ, Higgins JPT on behalf of the Statistical Methods Group of The Cochrane Collaboration. Statistical algorithms in Review Manager; August 2010. tech.cochrane.org/revman/documentation/statistical-methods-in-revman-5.pdf (accessed 11 January 2017).
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). 4th Edition. Arlington, VA: American Psychiatric Press, Inc., 2000.
16. Ford O, Lethaby A, Roberts H, Mol BW. Progesterone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2012, Issue 3. [DOI: 10.1002/14651858.CD003415.pub2]
17. Gianetto-Berruti A, Feyles V. Premenstrual syndrome. Minerva Ginecologica 2002;54(2):85-95.
18. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed prior to 4 November 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
19. Green LJ, O'Brien PMS, Panay N, Craig M on behalf of the Royal College of Obstetricians and Gynaecologists. Management of premenstrual syndrome. Br J Obst Gynaecol 2017;124:e73-e105.
20. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003;28(Suppl 3):1-23.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
22. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
23. O'Brien PMS, Bäckström T, Brown C, Dennerstein L, Endicott J, Epperson CN, et al. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus. Archives of Women's Mental Health 2011;14(1):13.
24. Johnson S. The epidemiology of premenstrual syndrome. Primary Psychiatry 2004;11(2):27-32.
25. Kaur G, Gonsalves L, Thacker HL. Premenstrual dysphoric disorder: a review for the treating practitioner. Cleveland Clinic Journal of Medicine 2004;71(4):303-5, 312-3, 317-8 passim.
26. Lopez LL, Kaptein AA, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD006586.pub4]
27. Marjoribanks J, Brown J, O'Brien PMS, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD001396.pub3]
28. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ 2009;339:2535.
29. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical Care 2003;41(3):582-92.
30. O'Brien P, Ismail K, Dimmock P. Premenstrual syndrome. In: Shaw R, Soutter W, Stanton S editor(s). Gynaecology. 3rd Edition. London: Churchill Livingston, 2003:401-11.
31. O'Brien S, Rapkin A, Dennerstein L, Nevatte T. Diagnosis and Management of Premenstrual Syndrome. BMJ 2011;342:d2994.
32. Panay N. Premenstrual syndrome: Making sense of the options. Pulse 2004;65(8):50-4.
33. Rapkin AJ, Kuo J. The Premenstrual Syndromes. In: O'Brien PMS, Rapkin A, Schmidt P editor(s). PMS & PMDD. London: Informa Healthcare, 2007:69-83.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
35. Roberts HE, Hickey M, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia: A Cochrane review summary. Maturitas 2014;77(1):4-6. [A Cochrane review summary. Maturitas, ]
36. Sackett DL, Deeks JJ, Altman DG. Down with odds ratios!. Evidence Based Medicine 1996;1(6):164-6.